Sipuleucel-T immunotherapy for men with metastatic castration-resistant prostate cancer (mCRPC) is associated with longer survival among those with lower disease burden, according to a new analysis of real-world data presented at the 20th annual meeting of the Society of Urologic Oncology in Washington, DC.

Sipuleucel-T is an autologous cell-based immunotherapy that the FDA approved in 2010 for use in men with asymptomatic or minimally symptomatic mCRPC. In the previous IMPACT trial, treatment with sipuleucel-T was associated with a significant 22% decreased risk of death compared with placebo. The trial had excluded patients with PSA levels below 5 ng/mL.

The new finding is from a study of men in the PROCEED (PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data) registry who received 1 or more infusions of sipuleucel-T and had a reported baseline PSA value. Ronald F. Tutrone, MD, of Chesapeake Urology and the Greater Baltimore Medical Center in Towson, Maryland, and colleagues divided patients according to PSA level: below 5.0 and 5.0 ng/mL or higher (low- and high-PSA groups, respectively). The low- and high-PSA groups included 451 and 1435 men, respectively.

The median survival time was significantly longer in the low-PSA than high-PSA group (47.9 vs 26.4 months), according to the investigators.


Continue Reading

Results also showed that black men had a significantly lower risk of death than white men regardless of baseline PSA level. Among men in the low-PSA group, black men had a 51% decreased risk of death compared with white men. In the high-PSA group, black men had a 20% decreased risk of death.

Use of sipuleucel-T in men with lower disease burden may improve their survival, Dr Tutrone and his colleagues concluded.

Related Articles

Reference

Tutrone R, Pieczonka C, Nordquist L, et al. Survival outcomes for metastatic castration-resistant prostate cancer with PSA less than 5 ng/mL treated with sipuleucel-T, overall and by race: Data from the PROCEED registry. Presented at the 20th annual meeting of the Society of Urologic Oncology held December 4 to 6 in Washington, DC. Poster 74.